Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07482813
PHASE3

An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Sponsor: Paradigm Therapeutics

View on ClinicalTrials.gov

Summary

The objective is to characterize the continued safety of SD-101 cream containing 6% allantoin in the treatment of the skin in patients with Simplex, Recessive Dystrophic, or JEB-nH EB.

Official title: An Open Label Extension, Multi-Center Study to Evaluate the Safety of SD 101 Cream in Subjects With Epidermolysis Bullosa

Key Details

Gender

All

Age Range

28 Days - 12 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-07-15

Completion Date

2027-08-19

Last Updated

2026-03-19

Healthy Volunteers

No

Interventions

DRUG

SD-101 Dermal Cream (6%)

SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.